Will Gibson

Title: Will Gibson: Innovator in Chimeric Antigen Receptor Technology

Introduction

Will Gibson is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of immunology, particularly in the development of chimeric antigen receptors. His innovative work aims to enhance the effectiveness of immune cell therapies in treating cancer.

Latest Patents

Gibson holds a patent for a "Universal platform for preparing an inhibitory chimeric antigen receptor (iCAR)." This invention provides a method for identifying targets to create iCARs or protective chimeric antigen receptors (pCARs). These receptors are designed to prevent or reduce unwanted activation of effector immune cells. The patent also includes a list of iCAR targets, vectors, and transduced effector immune cells that incorporate the nucleic acid molecule. Furthermore, it outlines methods for cancer treatment that involve administering these transduced immune cells.

Career Highlights

Throughout his career, Will Gibson has worked with notable companies such as Immpact Bio Ltd. and Gavish-Galilee Bio Applications Ltd. His experience in these organizations has allowed him to refine his expertise in the field of biotechnology and immunotherapy.

Collaborations

Gibson has collaborated with several professionals in his field, including Gideon Gross and Dvir Dahary. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Will Gibson is a key figure in the innovation of chimeric antigen receptor technology, with a focus on improving cancer treatment methods. His contributions through patents and collaborations highlight his commitment to advancing medical science.